With regard to South Korea, Novartis fixed particular very well-publicized allegations that it had made inappropriate payments to HCPs in South Korea through round tables and 3rd-party clinical journals. Novartis Korea allegedly transmitted improper honoraria to HCPs for round tables by way of medical journals in order to avoid compliance scrutiny,